FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406260445> ?p ?o ?g. }

• W2406260445 abstract "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a 5 year survival rate of less than 5%. Deaths caused by pancreatic cancer are projected to exceed the number from colorectal carcinoma by 2020, making PDAC the second leading cause of cancer-related death in the United States, behind only NSCLC. At the molecular level, PDAC is enriched for a number of genetic events central to CDK4/6:CyclinD1 control of cell cycle progression - 90% of tumors harbor oncogenic KRAS mutations, which are synthetic lethal with CDK4/6 inhibition, while the majority of PDAC cases also feature loss of p16INK4A, the endogenous inhibitor of CDK4/6. Rb loss is uncommon in PDAC and phosphorylation of Rb, the canonical CDK4/6 substrate, is detectable at high frequencies, suggesting that aberrant CDK4/6 signaling may be central to loss of cell cycle control in pancreatic cancer. To determine the significance of CDK4/6 activity in pancreatic cancer, patient-derived xenograft models of early and late stage disease were used to evaluate the selective CDK4/6 inhibitor, palbociclib. Combinatorial efficacy of palbociclib with the standard of care agents, Gemcitabine and nab-paclitaxel (Gem/nab-Pac) was also assessed. The majority of models display greater than 50% tumor growth inhibition following treatment with single agent palbociclib, which is comparable to the response to Gem/nab-Pac in those models. Addition of palbociclib to Gem/nab-Pac confers further benefit in most models by increasing the degree of tumor response on therapy and/or maintaining tumor response after drug removal. To dissect the driver activities in the triplet combination, palbociclib was assessed in combination with either Gem or nab-Pac in a series of tumor growth inhibition/delay studies. Palbociclib and nab-Pac are the dominant agents in the combination - palbociclib/nab-Pac doublet activity surpasses the anti-tumor effects of Gem/nab-Pac in the majority of models, while palbociclib/nab-Pac is equivalent or superior to the triple combination in all models. In contrast, the addition of palbociclib to Gem yields little signs of positive combinatorial activity. Based on these data, the palbociclib/nab-Pac combination will be evaluated in an upcoming clinical trial for PDAC patients. Ongoing pre-clinical studies are focused on the mechanistic and molecular basis for the robust activity of the palbociclib/nab-Pac combination in pancreatic cancer. Citation Format: Manuel Hidalgo, Camino Menendez, Jing Yuan, Beatriz Salvador, Tao Xie, John Chionis, Pedro Lopez-Casas, Xianxian Zheng, James Hardwick, Paul Rejto, Peter Olson, Todd VanArsdale, David J. Shields. Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A42." @default.
• W2406260445 created "2016-06-24" @default.
• W2406260445 creator A5004649875 @default.
• W2406260445 creator A5006964063 @default.
• W2406260445 creator A5011377778 @default.
• W2406260445 creator A5016938641 @default.
• W2406260445 creator A5031270954 @default.
• W2406260445 creator A5042557251 @default.
• W2406260445 creator A5050783613 @default.
• W2406260445 creator A5059897119 @default.
• W2406260445 creator A5060336842 @default.
• W2406260445 creator A5063855097 @default.
• W2406260445 creator A5082250124 @default.
• W2406260445 creator A5086660695 @default.
• W2406260445 creator A5091310917 @default.
• W2406260445 date "2015-12-01" @default.
• W2406260445 modified "2023-09-27" @default.
• W2406260445 title "Abstract A42: Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma" @default.
• W2406260445 doi "https://doi.org/10.1158/1535-7163.targ-15-a42" @default.
• W2406260445 hasPublicationYear "2015" @default.
• W2406260445 type Work @default.
• W2406260445 sameAs 2406260445 @default.
• W2406260445 citedByCount "0" @default.
• W2406260445 crossrefType "proceedings-article" @default.
• W2406260445 hasAuthorship W2406260445A5004649875 @default.
• W2406260445 hasAuthorship W2406260445A5006964063 @default.
• W2406260445 hasAuthorship W2406260445A5011377778 @default.
• W2406260445 hasAuthorship W2406260445A5016938641 @default.
• W2406260445 hasAuthorship W2406260445A5031270954 @default.
• W2406260445 hasAuthorship W2406260445A5042557251 @default.
• W2406260445 hasAuthorship W2406260445A5050783613 @default.
• W2406260445 hasAuthorship W2406260445A5059897119 @default.
• W2406260445 hasAuthorship W2406260445A5060336842 @default.
• W2406260445 hasAuthorship W2406260445A5063855097 @default.
• W2406260445 hasAuthorship W2406260445A5082250124 @default.
• W2406260445 hasAuthorship W2406260445A5086660695 @default.
• W2406260445 hasAuthorship W2406260445A5091310917 @default.
• W2406260445 hasConcept C121608353 @default.
• W2406260445 hasConcept C126322002 @default.
• W2406260445 hasConcept C143998085 @default.
• W2406260445 hasConcept C2775930923 @default.
• W2406260445 hasConcept C2777292972 @default.
• W2406260445 hasConcept C2779744173 @default.
• W2406260445 hasConcept C2780210213 @default.
• W2406260445 hasConcept C2780258809 @default.
• W2406260445 hasConcept C2781182431 @default.
• W2406260445 hasConcept C2781187634 @default.
• W2406260445 hasConcept C502942594 @default.
• W2406260445 hasConcept C526805850 @default.
• W2406260445 hasConcept C530470458 @default.
• W2406260445 hasConcept C71924100 @default.
• W2406260445 hasConceptScore W2406260445C121608353 @default.
• W2406260445 hasConceptScore W2406260445C126322002 @default.
• W2406260445 hasConceptScore W2406260445C143998085 @default.
• W2406260445 hasConceptScore W2406260445C2775930923 @default.
• W2406260445 hasConceptScore W2406260445C2777292972 @default.
• W2406260445 hasConceptScore W2406260445C2779744173 @default.
• W2406260445 hasConceptScore W2406260445C2780210213 @default.
• W2406260445 hasConceptScore W2406260445C2780258809 @default.
• W2406260445 hasConceptScore W2406260445C2781182431 @default.
• W2406260445 hasConceptScore W2406260445C2781187634 @default.
• W2406260445 hasConceptScore W2406260445C502942594 @default.
• W2406260445 hasConceptScore W2406260445C526805850 @default.
• W2406260445 hasConceptScore W2406260445C530470458 @default.
• W2406260445 hasConceptScore W2406260445C71924100 @default.
• W2406260445 hasLocation W24062604451 @default.
• W2406260445 hasOpenAccess W2406260445 @default.
• W2406260445 hasPrimaryLocation W24062604451 @default.
• W2406260445 hasRelatedWork W1504271024 @default.
• W2406260445 hasRelatedWork W2324819167 @default.
• W2406260445 hasRelatedWork W2400253579 @default.
• W2406260445 hasRelatedWork W2477337512 @default.
• W2406260445 hasRelatedWork W2484443630 @default.
• W2406260445 hasRelatedWork W2555295775 @default.
• W2406260445 hasRelatedWork W2562448371 @default.
• W2406260445 hasRelatedWork W2592013647 @default.
• W2406260445 hasRelatedWork W2739877429 @default.
• W2406260445 hasRelatedWork W2740043255 @default.
• W2406260445 hasRelatedWork W2740410039 @default.
• W2406260445 hasRelatedWork W2741220559 @default.
• W2406260445 hasRelatedWork W2886104010 @default.
• W2406260445 hasRelatedWork W2887682467 @default.
• W2406260445 hasRelatedWork W2954718568 @default.
• W2406260445 hasRelatedWork W2994730469 @default.
• W2406260445 hasRelatedWork W2995381091 @default.
• W2406260445 hasRelatedWork W3013880900 @default.
• W2406260445 hasRelatedWork W3083400309 @default.
• W2406260445 hasRelatedWork W3083739730 @default.
• W2406260445 isParatext "false" @default.
• W2406260445 isRetracted "false" @default.
• W2406260445 magId "2406260445" @default.
• W2406260445 workType "article" @default.